期刊文献+

氯化镧抑制前列腺癌细胞DU145的生长和迁移 被引量:5

Lanthanum inhibits prostate cancer Du145 cells growth and migration
原文传递
导出
摘要 为探索稀土化合物在防治前列腺癌转移方面的潜在药理作用,研究了氯化镧对人前列腺癌细胞DU145的生长和迁移的影响及其机理.基于MTT实验结果得知,LaCl3显著抑制DU145细胞的增殖,且呈浓度依赖关系;克隆形成实验也显示了LaCl3抑制克隆形成.结果表明,LaCl3能够抑制前列腺癌细胞的生长.此外,利用划痕损伤实验证明,10?5mol/LLaCl3可以抑制细胞迁移,并且在该浓度下,LaCl3对细胞黏附和伸展也有抑制作用.进一步的机制研究表明,不同浓度LaCl3均可下调ERK和P38的磷酸化水平;而百日咳毒素PTx,一种Gi蛋白抑制剂,减弱了LaCl3对ERK和P38磷酸化的抑制作用以及其对DU145细胞克隆形成和伸展的抑制作用.结果表明,LaCl3能够抑制前列腺癌细胞DU145的生长和迁移,该作用与ERK和P38磷酸化水平降低有关,可能是通过PTx敏感的Gi蛋白信号通路介导的. Lanthanides compounds have been reported to perform anticancer activity in certain cancer cells,but there have been few reports looking specifically at the effects of these compounds on prostate cancer.In this study,we evaluated the effects of lanthanum chloride (LaCl3) on the proliferation,adhesion and migration ability of androgen-independent prostate cancer DU145 cells.The results of MTT assay showed that LaCl3 treatment inhibited the proliferation of DU-145 cells in a dose-dependent manner.Using colony forming assay,LaCl3 treatment led to reduced colony forming ability of DU145 cells.Further observations demonstrated that the presence of LaCl3 decreased adhesive capacity,cell-surface area and migration in DU145 cells.In addition,LaCl3 treatment inhibited phosphorylation of extracellular signal-regulated kinase (ERK) and P38 MAPK kinase of DU145 cells.Moreover,pretreatment of the cells with pertussis toxin (PTx),a Gi protein inhibitor,abolished LaCl3-induced ERK and P38 phosphorylation,as well as colony formation and cell-surface area.In conclusion,the findings suggest that LaCl3 inhibits in vitro DU145 cells growth and migration,and the effect is partly linked to Gi protein signaling pathway.
出处 《科学通报》 EI CAS CSCD 北大核心 2010年第23期2289-2295,共7页 Chinese Science Bulletin
基金 国家自然科学基金(20637010) 高等学校博士学科点专项科研基金(200800011058)资助项目
关键词 氯化镧 前列腺癌 生长 迁移 Gi蛋白信号通路 LaCl3 prostate cancer growth migration Gi protein signaling
  • 相关文献

参考文献24

  • 1Nelson W G, De Marzo A M, Isaacs W B. Prostate cancer. N Engl J Med, 2003, 349:366--381.
  • 2Mundy G R. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer, 2002, 2:584--593.
  • 3Isaacs J T. Role of androgens in prostatic cancer. Vitam Horm, 1994, 49:433--502.
  • 4Hammond L A, Brown G, Keedwell R G, et al. The prospects of retinoids in the treatment of prostate cancer. Anticancer Drugs, 2002, 13: 781-790.
  • 5Fricker S P. The therapeutic application of lanthanides. Chem Soc Rev, 2006, 35:524--533.
  • 6Kapoor S. Lanthanum and its rapidly emerging role as an anti-carcinogenic agent. J Cell Biochem, 2009, 106:193.
  • 7Zhao X Y, Schneider D, Biroc S L, et al. Targeting tomoregulin for radioimmunotherapy of prostate cancer. Cancer Res, 2005, 65: 2846-- 2853.
  • 8Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev, 2006, 35:512-523.
  • 9Kostova I, Momekov G, Zaharieva M, et al. Cytotoxic activity of new lanthanum (III) complexes of bis-coumarins. Eur J Med Chem, 2005, 40:542-551.
  • 10Heffeter P, Jakupec M A, Korner W, et al. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol, 2007, 73:1873--1886.

同被引文献80

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部